CMS Sticks To Biosimilar Proposal In Face Of Strong Opposition; Pays For Advance Care Plans

The physician pay rule that CMS published Friday (Oct. 30) is broad, but two policies caught the immediate attention of lawmakers and special interest groups: biosimilar and advance care planning reimbursement. Despite strong pushback from drug makers and many lawmakers, CMS stuck to its earlier proposal to place biosimilars in single billing codes. Paying doctors for consulting patients and their families about options at the end-of-life did not get pushback when CMS proposed it earlier this year, but during the...

CMS Sticks To Biosimilar Proposal In Face Of Strong Opposition; Pays For Advance Care Plans

You've followed a link to an article or document on InsideHealthPolicy.com.There are two ways you can access this content.

Subscriber Login

Take A Trial Subscription

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.